Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 95 peer-reviewed journal articles Updated
Medical Oncology

Pancreatic Small Cell Neuroendocrine Carcinoma: A Patient Guide

At a Glance

Pancreatic small cell neuroendocrine carcinoma is a rare, fast-growing cancer that needs expert pathology confirmation and full staging. Treatment usually starts with platinum-based chemotherapy plus etoposide, with molecular profiling and clinical trials considered early.

Pancreatic Small Cell Neuroendocrine Carcinoma (SC-NEC) is an exceptionally rare and aggressive form of cancer that requires a specialized approach from the moment of diagnosis. Unlike the more common slow-growing neuroendocrine tumors, SC-NEC is a “high-grade” and “poorly differentiated” cancer, meaning its cells divide rapidly and look very different from healthy pancreatic tissue [1]. Because it grows and spreads quickly, it is often managed as a systemic disease—one that is treated with systemic therapies as if it may be present throughout the body even if scans only show a single tumor, though selected localized cases may be evaluated for multimodality care [2].

The most critical first step in your journey is ensuring your diagnosis is accurate, as SC-NEC is frequently confused with other pancreatic cancers that require entirely different treatments. A precise diagnosis depends on an expert pathologist confirming “small cell morphology” and integrating clinical context with specific molecular markers, such as supportive abnormalities in the p53 and Rb1 proteins [3]. Distinguishing this cancer from a well-differentiated Grade 3 neuroendocrine tumor is vital because the two diseases respond to different types of chemotherapy [4]. This complexity is why seeking a second opinion at a high-volume, specialized neuroendocrine center is strongly advisable, provided it does not delay urgent care [5].

Once the diagnosis is confirmed, staging your cancer accurately is the next priority. This process typically involves a specialized pancreatic-protocol CT scan or MRI, and may include an FDG-PET scan to identify areas of high metabolic activity [6]. Because small cell cancer often starts in the lungs before spreading to other organs, your medical team will also carefully evaluate your chest to ensure the cancer originated in the pancreas [7]. This comprehensive view allows your doctors to map out the full extent of the disease and plan the most effective intervention.

Because of the fast-growing nature of SC-NEC, treatment typically begins with intensive, systemic chemotherapy rather than surgery. The common starting point is a combination of a platinum-based drug, such as cisplatin or carboplatin, with etoposide [8]. While the tumor often responds quickly to this approach, the aggressive nature of the disease means that experts also recommend early molecular profiling and the exploration of clinical trials [9]. This proactive strategy ensures that you are accessing the most advanced science and personalized options available, keeping you oriented and supported as you navigate this challenging diagnosis [10].

In this guide

7 chapters

01

Understanding Your Diagnosis: Pancreatic Small Cell Neuroendocrine Carcinoma

Learn what pancreatic small cell neuroendocrine carcinoma means, why expert pathology review matters, which scans may be needed, and how treatment planning starts.

02

Symptoms & Warning Signs of Pancreatic SC-NEC

Learn the symptoms of pancreatic SC-NEC, including jaundice, pain, weight loss, and emergency warning signs such as fever, bleeding, clots, and vomiting.

03

Pathology & Differential Diagnosis: Decoding Your Report

Learn how to read a pancreatic small cell neuroendocrine carcinoma pathology report, including Ki-67, mitotic rate, IHC, and the difference from NET G3.

04

Staging & Imaging for Pancreatic SC-NEC

Learn how pancreatic SC-NEC is staged with CT, MRI, FDG-PET, and DOTATATE scans, including how doctors check for spread and rule out a lung primary.

05

Standard of Care Treatment for Pancreatic SC-NEC

Learn pancreatic SC-NEC treatment options: platinum-etoposide chemotherapy, side effects, second-line care, clinical trials, and surgery for select cases.

06

Molecular Profiling & Clinical Trials for Pancreatic SC-NEC

Learn how molecular profiling and clinical trials can guide pancreatic SC-NEC care, including actionable mutations, immunotherapy markers, and trial timing.

07

Prognosis, Monitoring & Survivorship for Pancreatic SC-NEC

Learn about pancreatic SC-NEC prognosis, surveillance scans, palliative care, scanxiety, nutrition, diabetes monitoring, and survivorship resources and care.

Common questions in this guide

What is pancreatic small cell neuroendocrine carcinoma?
Pancreatic small cell neuroendocrine carcinoma is a rare, high-grade cancer that can grow and spread quickly. Its cells look very different from normal pancreatic cells, and it behaves more aggressively than many slower-growing neuroendocrine tumors.
How is pancreatic small cell NEC confirmed?
An expert pathologist examines the tumor for small cell features and combines the tissue findings with clinical information and molecular markers such as p53 and Rb1 abnormalities. Confirming the diagnosis is important because this cancer is treated differently from a well-differentiated Grade 3 neuroendocrine tumor.
What scans are used to stage pancreatic small cell NEC?
Staging commonly includes a specialized CT scan or MRI designed to show the pancreas. An FDG-PET scan may also help identify the most active areas, and doctors usually evaluate the chest to make sure the cancer began in the pancreas rather than the lungs.
Why does treatment often start with chemotherapy instead of surgery?
This cancer can spread throughout the body quickly, even when scans show only one tumor, so treatment often begins with systemic chemotherapy. A common first treatment combines a platinum drug such as cisplatin or carboplatin with etoposide, while selected localized cases may be considered for multimodality treatment.
Should I seek a second opinion or ask about molecular profiling?
A review by a pathologist and oncology team experienced with high-grade neuroendocrine cancers can help confirm the diagnosis and treatment plan, as long as it does not delay urgent care. Early molecular profiling and discussion of clinical trials may identify additional treatment options.

Get notified when new evidence is published on pancreatic small cell neuroendocrine carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (10)
  1. 1

    Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.

    Hijioka S, Hosoda W, Matsuo K, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2017; (23(16)):4625-4632 doi:10.1158/1078-0432.CCR-16-3135.

    PMID: 28455360
  2. 2

    European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma.

    Sorbye H, Grande E, Pavel M, et al.

    Journal of neuroendocrinology 2023; (35(3)):e13249 doi:10.1111/jne.13249.

    PMID: 36924180
  3. 3

    A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.

    Tang LH, Basturk O, Sue JJ, Klimstra DS

    The American journal of surgical pathology 2016; (40(9)):1192-202 doi:10.1097/PAS.0000000000000662.

    PMID: 27259015
  4. 4

    Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.

    Umetsu SE, Kakar S, Basturk O, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2023; (36(3)):100065 doi:10.1016/j.modpat.2022.100065.

    PMID: 36788102
  5. 5

    Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Shah MH, Goldner WS, Benson AB, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(7)):839-868.

    PMID: 34340212
  6. 6

    Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.

    Panagiotidis E, Alshammari A, Michopoulou S, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017; (58(1)):91-96 doi:10.2967/jnumed.116.178095.

    PMID: 27516446
  7. 7

    Pancreatic Neuroendocrine Tumors: From Benchside to Surgical Treatment.

    Conzo G, Mongardini FM, Paolicelli M, et al.

    Medicina (Kaunas, Lithuania) 2026; (62(3)) doi:10.3390/medicina62030479.

    PMID: 41901560
  8. 8

    Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.

    Morizane C, Machida N, Honma Y, et al.

    JAMA oncology 2022; (8(10)):1447-1455 doi:10.1001/jamaoncol.2022.3395.

    PMID: 35980649
  9. 9

    Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.

    Mosele F, Remon J, Mateo J, et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2020; (31(11)):1491-1505 doi:10.1016/j.annonc.2020.07.014.

    PMID: 32853681
  10. 10

    Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.

    Eads JR, Halfdanarson TR, Asmis T, et al.

    Endocrine-related cancer 2023; (30(8)).

    PMID: 37184955

This page is for informational purposes only and does not constitute medical advice about pancreatic small cell neuroendocrine carcinoma. An expert pathologist and oncology team should interpret your diagnosis and discuss treatment options with you.